

Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-May-2019  
Document Type: USP Monographs  
DocId: GUID-6E97A0F2-9D30-467C-A9A7-D69607493240\_5\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M40620\\_05\\_01](https://doi.org/10.31003/USPNF_M40620_05_01)  
DOI Ref: u0khu

© 2025 USPC  
Do not distribute

## Isophane Insulin Suspension

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click

<https://www.uspnf.com/rb-isophane-insulin-suspension-20190401>

### DEFINITION

Isophane Insulin Suspension is a sterile suspension of zinc–insulin crystals and Protamine Sulfate in buffered Water for Injection, combined in a manner such that the solid phase of the suspension consists of crystals composed of insulin, protamine, and zinc. The Protamine Sulfate is prepared from the sperm or from the mature testes of fish belonging to the genus *Oncorhynchus* Suckley, or *Salmo* L. (Fam. Salmonidae). Its potency, based on the sum of its insulin and desamido insulin components, is NLT 95.0% and NMT 105.0% of the potency stated on the label, expressed in USP Insulin Units/mL.

### IDENTIFICATION

**Change to read:**

- **A.** The retention time of the insulin ▲<sub>pork</sub>▲ (RB 1-May-2019) peak of *Sample solution A* or *Sample solution B* corresponds to that of the ▲<sub>main</sub> peak▲ (RB 1-May-2019) of the *Identification solution*, as obtained in the *Assay*▲, and no other significant peaks are observed.▲ (RB 1-May-2019) [NOTE—It may be necessary to inject a mixture of *Sample solution* and *Identification solution*.]

### ASSAY

**Change to read:**

#### • PROCEDURE

**Solution A:** Dissolve 28.4 g of [anhydrous sodium sulfate](#) in 1000 mL of water. Pipet 2.7 mL of [phosphoric acid](#) into the solution, and adjust with [ethanolamine](#) to a pH of 2.3, if necessary.

**Mobile phase:** [Acetonitrile](#) and *Solution A* (26:74). [NOTE—The [acetonitrile](#) is warmed to NLT 20° to avoid precipitation.]

**System suitability solution:** 1.5 mg/mL of ▲<sub>pork</sub>▲ (RB 1-May-2019) insulin pork in 0.01 N [hydrochloric acid](#).▲ (RB 1-May-2019) Allow to stand at room temperature for NLT 3 days to obtain a solution containing NLT 5% of A-21 desamido insulin.

**Identification solution:** 0.6 mg/mL of ▲<sub>pork</sub>▲ (RB 1-May-2019) [USP Insulin Pork RS](#) in 0.01 N [hydrochloric acid](#). [NOTE—The *Identification solution* may be stored at room temperature for up to 12 h or in a refrigerator for up to 48 h.]

**Standard solution:** 1.5 mg/mL of ▲<sub>pork</sub>▲ (RB 1-May-2019) [USP Insulin Pork RS](#) in 0.01 N [hydrochloric acid](#).▲ (RB 1-May-2019)

**Sample solution A** (for Suspension labeled as containing 40 USP Insulin Units/mL): Add 2.5 µL of 9.6 N [hydrochloric acid](#) for each milliliter of an accurately measured volume of Suspension. Allow the suspension to clarify, and mix.

**Sample solution B** (for Suspension labeled as containing 100 USP Insulin Units/mL): Add 2.5 µL of 9.6 N [hydrochloric acid](#) for each milliliter of an accurately measured volume of Suspension. Allow the suspension to clarify, and mix. [NOTE—Pooling several package units may be necessary to obtain sufficient volume of the sample.] Pipet 2 mL of this solution into a 5-mL volumetric flask, dilute with 0.01 N [hydrochloric acid](#) to volume, and mix.

### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 214 nm

**Column:** 4.6-mm × 15-cm; packing [L1](#)

**Column temperature:** 40°

**Flow rate:** 1 mL/min

**Injection volume:** 20 µL

### System suitability

**Samples:** *System suitability solution* and *Standard solution*

**Suitability requirements**

**Resolution:** NLT 2.0 between insulin and A-21 desamido insulin, *System suitability solution*

**Tailing factor:** NMT 1.8 for the insulin peak, *System suitability solution*

**Relative standard deviation:** NMT 1.6%, *Standard solution*

**Analysis**

**Samples:** *Identification solution, Standard solution, and either Sample solution A or Sample solution B*

Measure the peak responses for insulin and A-21 desamido insulin  $\Delta$  (RB 1-May-2019), using the chromatogram of the *Identification solution* to identify the insulin peaks.

$\Delta$  (RB 1-May-2019) Calculate the potency, in USP Insulin Units/mL, in the portion of Suspension taken:

$$\text{Result} = (\Sigma r_U / \Sigma r_S) \times C_S \times D$$

$r_U$  = sum of the peak responses of insulin and A-21 desamido insulin from the *Sample solution*

$r_S$  = sum of the peak responses of insulin and A-21 desamido insulin from the *Standard solution*

$C_S$  = concentration of  $\Delta$  (RB 1-May-2019) [USP Insulin Pork RS](#) in the *Standard solution* (USP Insulin Units/mL)

$D$  = dilution factor used to prepare the *Sample solution*

$\Delta$  (RB 1-May-2019)

**Acceptance criteria:** 95.0%–105.0% of the potency stated on the label, expressed in USP Insulin Units/mL

**OTHER COMPONENTS**

- [ZINC DETERMINATION \(591\)](#): 10–40 µg for every 100 USP Insulin Units

**PRODUCT-RELATED SUBSTANCES AND IMPURITIES**

- [PHYSICOCHEMICAL ANALYTICAL PROCEDURES FOR INSULINS \(121.1\), Limit of High Molecular Weight Proteins](#): Proceed as directed in the chapter, except for the *Sample solution*. It meets the requirements.

**Sample solution:** Quantitatively add 4 µL of 6 N [hydrochloric acid](#) to each milliliter of an accurately measured volume of Suspension, and mix.

**Acceptance criteria:** NMT 3.0%

**SPECIFIC TESTS**

- [INSULIN IN THE SUPERNATANT](#)

**Sample solution:** Centrifuge 10 mL of the Suspension at 1500  $\times g$  for 10 min. Use the supernatant.

**Analysis:** Determine the insulin content of the *Sample solution* by a suitable method.

**Acceptance criteria:** NMT 1.0 USP Insulin Unit/mL

- [pH \(791\)](#): 7.0–7.8

**BACTERIAL ENDOTOXINS TEST (85)**: NMT 80 USP Endotoxin Units per 100 USP Insulin Units

**STERILITY TESTS (71), Test for Sterility of the Product to Be Examined, Membrane Filtration**: Meets the requirements when tested as directed in the chapter and the Suspension being filtered immediately after it has been put into a solution using a validated suitable solvent

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in the unopened, multiple-dose container provided by the manufacturer. Do not repackage. Store in a refrigerator, protect from sunlight, and avoid freezing.

**Change to read:**

- **LABELING:** Label it as  $\Delta$  (RB 1-May-2019) porcine  $\Delta$  (RB 1-May-2019). If the Isophane Insulin Suspension is made from insulin that is purified, label it as such. The Suspension container label states that the Suspension is to be shaken carefully before use. Label it to state that it is to be stored in a refrigerator and that freezing is to be avoided. The label states the potency in USP Insulin Units/mL.

**Change to read:**

- [USP REFERENCE STANDARDS \(11\)](#).

$\Delta$  (RB 1-May-2019)

[USP Insulin Pork RS](#)

Topic/Question	Contact	Expert Committee
INSULIN ISOPHANE INJECTABLE SUSPENSION	<a href="#">Jennifer Tong Sun</a> Senior Scientist II	BIO2 Biologics Monographs 2 - Proteins

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 44(4)

**Current DocID: GUID-6E97A0F2-9D30-467C-A9A7-D69607493240\_5\_en-US**

**DOI: [https://doi.org/10.31003/USPNF\\_M40620\\_05\\_01](https://doi.org/10.31003/USPNF_M40620_05_01)**

**DOI ref: [u0khu](#)**

OFFICIAL